The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: Implications for diagnosis and treatment

Epilepsy and Behavior

Volumn 13, Issue 1, 2008, Pages 12-24

  Guille, Constance ^a   Spencer, Susan ^a   Cavus, Idil ^a   Epperson, C Neill ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminobutyric acid; Allopregnanolone; Catemenial epilepsy; Estradiol; Glutamate; Menstrual cycle linked disorders; Neuropsychiatric disorder; Premenstrual dysphoric disorder; Progesterone; Seizure disorder

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; ALPRAZOLAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CLOBAZAM; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; FLUOXETINE; GANAXOLONE; GLUTAMIC ACID; GONADORELIN; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; NEUROTRANSMITTER; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PROGESTERONE; PROGESTERONE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; VENLAFAXINE; YAZ 24;

ADD ON THERAPY; CATAMENIAL EPILEPSY; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; MENSTRUAL CYCLE; MENTAL DISEASE; NEUROBIOLOGY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PHENOMENOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHOPATHY; REVIEW;

EPILEPSY; ESTRADIOL; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; PROGESTERONE;

EID: 46549086850     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.02.004     Document Type: Review

References (117)

1. Hermann B.P., Seidenberg M., and Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 41 Suppl. 2 (2000) S31-S41
2. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, severity, and comorbidity of 12 month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 (2005) 617-627
3. Filipcić I., Popović-Grle S., Marcinko D., et al. Screening for depression disorders in patients with chronic somatic illness. Coll Antropol 31 (2007) 139-143
4. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., and Nelson C.B. Sex and depression in the National Comorbidity Survey: I Lifetime prevalence, chronicity and recurrence. J Affect Disord 29 (1993) 85-96
5. Logothethis J., Harner R., Morrell R., and Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 9 (1959) 352-360
6. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 54 (1976) 321-347
7. Herzog A.G., Klein P., and Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia 38 (1997) 1082-1088
8. Turner K.P., Franza A., Fumarola C., et al. Postpartum depression in women with epilepsy versus women without epilepsy. Epilepsy Behav 9 (2006) 293-297
9. Harden C. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 40 (1999) 1402
10. Freeman E.W., Sammel M.D., Liu L., Garcia C.R., Nelson D., and Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 61 (2004) 62-70
11. Schmidt P.J. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 118 12B (2005) 54S-58S
12. Soares C.N., Prauty, Born L., and Steiner M. Treatment of menopause-related mood disturbances. CNS Spectr 10 (2005) 489-497
13. Reddy D.S. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 15 (2003) 179-234
14. Backstrom T., Andersson A., Andree L., et al. Pathogenesis of menstrual cycle-linked CNS disorders. Ann NY Acad Sci 1007 (2003) 42-53
15. Reddy D.S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 62 (2004) 99-118
16. Herzog A.G., Harden C.L., Liporace J., et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 56 (2004) 431-434
17. Foldvary-Schaefer N., and Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 61 (2003) S2-S15
18. Scharfman H.E., and MacLusky N.J. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia 47 (2006) 1423-1440
19. Veliskova J. Estrogens and epilepsy: why are we so excited?. Neuroscientist 13 (2007) 77-88
20. Backstrom T., Andree L., Birzniece V., et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 17 (2003) 325-342
21. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., and Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338 (1998) 209-216
22. Mensah-Nyagan A.G., Do-Rego J.L., Beaujean D., Luu-The V., Pelletier G., and Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev 51 (1999) 63-81
23. Amin Z., Mason G.F., Cavus I., Krystal J.H., Rothman D.L., and Epperson C.N. Interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. Pharmacol Biochem Behav 84 (2006) 635-643
24. Backstrom T., Gee K.W., Lan N., Sorensen M., and Wahlstrom G. Steroids in relation to epilepsy and anaesthesia. Ciba Found Symp 153 (1990) 225-230
25. Cheney D.L., Uzunov D., Costa E., and Guidotti A. Gas chromatographic-mass fragmentographic quantitation of 3 alpha-hydroxy-5 alpha-pregnan-20-one (allopregnanolone) and its precursors in blood and brain of adrenalectomized and castrated rats. J Neurosci 15 (1995) 4641-4650
26. Schumacher M., Weill-Engerer S., Liere P., et al. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 71 (2003) 3-29
27. Rasmusson A.M., Pinna G., Paliwal P., et al. Decreased cerebrospinal fluid allogregnanolone levels in women with posttraumatic stress disorder. Biol Psychiatry 60 (2006) 704-713
28. Kim Y.S., Zhang H., and Kim H.Y. Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. Anal Biochem 277 (2000) 187-195
29. Mohammed S., Abolhassan A., and Pourgholami M.H. Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats. Epilepsy Res 30 (1998) 195-202
30. Morrell M.J. Epilepsy in women: the science of why it is special. Neurology 53 4,Suppl.1 (1999) S42-S48
31. Jacono J.J., and Robertson J.M. The effects of estrogen, progesterone, and ionized calcium on seizures during the menstrual cycle of epileptic women. Epilepsia 28 (1987) 571-577
32. Smith B.D., Waterhouse D.J., and Woodward S.S. Locally applied estrogens potentiate glutamate-evoked excitation of cerebellar Purkinje cells. Brain Res 475 (1988) 272-282
33. Wong M., and Moss R.L. Patch-clamp analysis of direct steroidal modulation of glutamate receptor-channels. J Neuroendocrinol 6 (1994) 347-355
34. Woolley C.S., Weiland N.G., McEwen B.S., and Schwartzkroin P.A. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 17 (1997) 1848-1859
35. Woolley C.S., and McEwen B.S. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 12 (1992) 2549-2554
36. Murphy D.D., and Segal M. Progesterone prevents estradiol-induced dendritic spine formation in cultured hippocampal neurons. Neuroendocrinology 72 (2000) 133-143
37. Smith S.S. Withdrawal properties of a neuroactive steroid: implications for GABA(A) receptor gene regulation in the brain and anxiety behavior. Steroids 67 (2002) 519-528
38. Selye H. The antagonism between anesthetic steroid hormones and pentamethylenetetrazol (metrazol). J Lab Clin Med 27 (1942) 1051-1053
39. Frye C.A., Rhodes M.E., Walf A., and Harney J. Progesterone reduces phentylenetetrazol-induced ictal activity of wild type mice but not those deficient in type I 5α-reductase. Epilepsia 43 Suppl. 5 (2002) 14-17
40. Herzog A.G., Seibel M.M., Schomer D.L., Vaitukaitis J.L., and Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 43 (1986) 341-346
41. Fawley J.A., Pouliotet W.A., and Dudek F.E. Epilepsy and reproductive disorders: the role of the gonadotropin-releasing hormone network. Epilepsy Behav 8 (2006) 477-482
42. Herzog A.G. Clomiphene therapy in epileptic women with menstrual disorders. Neurology 38 (1988) 432-434
43. Gulinello M., Gong Q.H., and Smith S.S. Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology: a comparison with female rats. Neuropharmacology 43 (2002) 701-714
44. Smith S.S., Ruderman Y., Frye C., Homanics G., and Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology 186 (2006) 323-333
45. Maguire J.L., Stell B.M., Rafizadeh M., and Mody I. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 8 (2005) 797-804
46. Belelli D., and Lambery J.J. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Rev Neurosci 6 (2005) 565-575
47. Bitran D., and Smith S.S. Termination of pseudopregnancy in the rat produces an anxiogenic-like response that is associated with an increase in benzodiazepine receptor binding density and a decrease in GABA-stimulated chloride influx in the hippocampus. Brain Res Bull 64 (2005) 511-518
48. Smolen A., Smolen T.N., and Han P.C. Alterations in regional brain GABA concentration and turnover during pregnancy. Pharmacol Biochem Behav 44 (1993) 63-69
49. Zhou X., and Smith S.S. Steroid requirements for regulation of the alpha4 subunit of the GABA(A) receptor in an in vitro model. Neurosci Lett 411 (2007) 61-66
50. Backstrom T., Snaders D., and Leask R.M. Mood, sexuality, hormones and the menstrual cycle: II. Hormone levels and their relation to premenstrual syndrome. Psychsom Med 45 (1983) 503-507
51. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
52. Schmidt P.J., Neiman L.K., Grover G.N., et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 324 (1991) 1174-1179
53. Hammarbäck S., and Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67 (1988) 159-166
54. Hammarbäck S., Ekholm U.B., and Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 125 (1991) 132-137
55. Pecins-Thompson M., Brown N.A., Kohama S.G., and Bethea C.L. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 16 (1996) 7021-7029
56. Sumner B.E.H., and Fink G. Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol Cell Neurosci 4 (1993) 83-92
57. Sumner B.E.H., and Fink G. Estrogen increases the density of 5-hydroxytryptamine 2A receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 54 (1995) 15-20
58. Kugaya A., Epperson C.A., Zoghbi S., et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 160 (2003) 1522-1524
59. Epperson C.N., Haga K., Mason G.F., et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59 (2002) 851-858
60. Schmidt P.J., Purdy R.H., Moore Jr. P.H., Paul S.M., and Ribinow D.R. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 79 (1994) 1256-1260
61. Wang M., Seippel L., Purdy R.H., and Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 81 (1996) 1076-1082
62. Lombardi I., Luisi S., Quirici B., et al. Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome. Gyn Endocrinol 18 (2004) 79-87
63. Monteleone P., Luisi S., Tonetti A., et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 142 (2000) 269-273
64. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., and Maheash V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 (1997) 709-714
65. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., and Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49 (2001) 788-797
66. Freeman E.W., Frye C.A., Rickels K., Martin P.A., and Smith S.S. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 22 (2002) 516-520
67. Klatzkin R.R., Morrow A.L., Light K.C., Pedersen C.A., and Girdler S.S. Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women. Biol Psychol 71 (2006) 2-11
68. Schmidt P.J., Grover G.N., Hoban M.C., and Rubinow D.R. State-dependent alterations in the perception of life events in menstrual-related mood disorders. Am J Psychiatry 147 (1990) 230-234
69. Cullberg J. Mood changes and menstrual symptoms with different estrogen/combinations: a double blind comparison with placebo. Acta Psychiatry Scand 236 (1972) 1-84
70. Graham C.A., and Sherwin B.B. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res 31 (1987) 45-53
71. Björn I., Sundström-Poromaa I., Bixo M., Nyberg S., Bäckström G., and Bäckström T. Increase in estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. Clin Endocrinol Metab 88 (2003) 2026-2030
72. Sundström I., Ashbrook D., and Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22 (1997) 25-38
73. Sundström I., Nyberg S., and Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17 (1997) 370-381
74. Sundström I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., and Bäckström T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive-steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67 (1998) 126-138
75. Nyberg S., Wahlström G., Bäckström T., and Sundström Poromaa I. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology 29 (2004) 767-777
76. Sundstrom I., and Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 23 (1998) 73-88
77. Wyatt K.M., Dimmock P.W., and O'Brien P.M. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 4 (2002) CD001396
78. Shen H., Gong Q.H., Yuan M., and Smith S.S. Short term steroid treatment increases delta GABA(A) receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. Neuropharmacology 49 (2005) 573-586
79. Smith S.S., and Gong Q.H. Ethanol effects on GABA-gated current in a model of increased alpha4betadelta GABAA receptor expression depend on time course and preexposure to low concentrations of the drug. Alcohol 41 (2007) 223-231
80. Smith M.J., Adams L.F., Schmidt P.J., Rubinow D.R., and Wassermann E.M. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry 54 (2003) 757-762
81. Epperson C.N., Pittman B., Czarkowski C., Stiklus S., Krystal J.H., and Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 32 (2007) 2190-2198
82. Facchinetti F., Romano G., Fava M., and Genazzani A.R. Lactate infusion induces panic attacks in patients with premenstrual syndrome. Psychosom Med 54 (1992) 288-296
83. Harrison W.M., Sandberg D., Gorman J.M., et al. Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatry Res 27 (1998) 183-192
84. Bauer J., Wildt L., Rugel D., and Stefan H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J Neurol 239 (1992) 284-286
85. Oinonen K.A., and Mazmanian D. To what extent do oral contraceptives influence mood and affect?. J Affect Disord 70 (2002) 229-240
86. Bancroft J., Boyle H., Warner P., and Fraser H.M. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 27 (1987) 171-182
87. Backstrom T., Hansson-Malmstrom Y., Lindhe B.A., Cavalli-Bjorkman B., and Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 46 (1992) 253-268
88. Kurshan N., and Epperson C.N. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Women's Ment Health 9 (2006) 1-14
89. Freeman E.W., Kroll R., Rapkin A., et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10 (2001) 561-569
90. Fenton C., Wellington K., Moen M.D., and Robinson D.M. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 67 (2007) 1749-1765
91. Paoletti A.M., Lello S., Fratta S., et al. Psychological effects of oral contraceptive formulation containing 3 mg of drospirenone plus 30 micrograms of ethinyl estradiol. Fertil Steril 81 (2004) 645-651
92. Majewska M.D., Demirgoren S., Spivak C.E., and London E.D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 526 (1990) 143-146
93. Bergeron R.J., Weimar W.R., Wu Q., Feng Y., and McManis J.S. Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study. J Med Chem 39 (1996) 5257-5266
94. 3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 92 (1995) 3774-3778
95. Follesa P., Porcu P., Sogliano C., et al. Changes in GABAA receptor gamma 2 subunit gene expression induced by long-term administration of oral contraceptives in rats. Neuropharmacology 42 (2002) 325-336
96. Simic B., Kniewald J., and Kniewald Z. Influence of ethynodiol diacetate on the formation of A-homo-3-oxa-5alpha-pregnane-4,20-dione in female rats. Endocrine Regul 32 (1998) 125-131
97. Dana-Haeri J., and Richens A. Effect of norethisterone on seizures associated with menstruation. Epilepsia 24 (1983) 377-381
98. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 46 (2005) 117-124
99. Mattson R.H., Cramer J.A., Caldwell B.V., and Siconolfi B.C. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 34 (1984) 1255-1258
100. Speroff L., Glass R.H., and Kase N.G. Clinical gynecology, endocrinology and infertility. 5th ed. (1994), Williams & Wilkins, Baltimore, MD
101. Wyatt K., Dimmock P., Jones P., Obhrai M., and O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Br Med J 323 (2001) 776-780
102. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 45 (1995) 1660-1662
103. Herzog A.G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 52 (1999) 1917-1918
104. Nohria G. Ganaxolone. Neurotheraputics 4 (2007) 102-105
105. Freeman E.W., Weinstock L., Rickels K., Sondheimer S.J., and Coutifaris C. A placebo-controlled study of effects of oral progesterone on performance and mood. Brit J Clin Pharmacol 33 (1992) 293-298
106. Freeman E.W., Rickels K., Sondheimer S.J., and Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274 (1995) 51-57
107. Uzunov D.P., Cooper T.B., Costa E., and Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci 93 (1996) 12599-12604
108. Uzunova V., Sheline Y., Davis J.M., Rasmusson, Uznov P., and Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95 (1998) 3239-3244
109. Pinna G., Costa E., and Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology 186 (2006) 362-372
110. Trimble M.R. On the use of tranquillisers in epilepsy. Epilepsia 43 Suppl. 2 (2002) 25-27
111. Reddy S.R., and Rogawski M.A. Stress induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci 42 (2002) 3795-3805
112. Feely M., Calvert R., and Gibson J. Clobazam in catamenial epilepsy: a model for evaluating anticonvulsants. Lancet 10 (1982) 71-73
113. Yonkers K.A., Pearlstein T., Fayyad R., and Gillespie J.A. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord 85 (2005) 3171-3172
114. Richman A., and Heinrichs S.C. Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res 74 (2007) 19-27
115. Jobe P.C., and Browning R.A. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7 (2005) 602-619
116. Reddy D.S., and Kulkarni S.K. Proconvulsant effects of neurosteroids pregnenolone sulfate and dehydroepiandrosterone sulfate in mice. Eur J Pharmacol 345 (1998) 55-59
117. Bergerson R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dihydroepiandosterone and its suppression by progesterone: effects medicated via sigma receptors. J Neurosci 16 (1996) 1193-1202